ArticleCureus2026
Clinical and Histopathological Predictors of Survival in Regional Lymph Node Metastases From Cutaneous Squamous Cell Carcinoma of the Head and Neck: A Retrospective Analysis.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCutaneous squamous cell carcinoma (cSCC) is a common skin cancer, with a subset demonstrating aggressive behaviour leading to regional lymph node metastases and poor prognosis. This study evaluated the clinical characteristics, prognostic factors, and survival outcomes in patients with nodal metastases from head and neck cSCC.
methodsA retrospective analysis was performed on 19 patients with histologically confirmed nodal metastases from cSCC treated between 2018 and 2023 at East Kent Hospitals NHS Trust. Data on patient demographics, tumour features, treatment, and follow-up were reviewed. Survival outcomes were estimated using Kaplan-Meier analysis, and univariate Cox regression identified potential prognostic factors for disease-free survival (DFS) and overall survival (OS).
resultsThe mean patient age was 84.3 years, with a male predominance (84.2%). Primary tumours were most frequently located on the scalp and cheek and were predominantly moderately or poorly differentiated. High-risk features included tumour size >2 cm, perineural invasion (36.8%), and extracapsular extension (52.6%). All patients underwent neck dissection, with 47% requiring additional parotidectomy; 94.7% received adjuvant radiotherapy. Despite this, the majority developed recurrence within 11 months. The five-year OS was 21.1%, and DFS was 5.3%. Tumour size was significantly associated with reduced DFS (p=0.026), while other pathological variables showed no independent effect.
conclusionsMetastatic cSCC of the head and neck carries a poor prognosis, even with aggressive multimodal therapy. High-risk pathological features remain key predictors of recurrence. Improved risk stratification and incorporation of novel systemic therapies may help improve long-term outcomes in this patient group.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.